 Daisy Alapat
Concepts (160)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 20 | 2024 | 2934 | 1.330 |
Why?
| | Flow Cytometry | 5 | 2018 | 475 | 0.880 |
Why?
| | Immunoglobulins | 2 | 2018 | 80 | 0.700 |
Why?
| | Immunoglobulin kappa-Chains | 2 | 2016 | 22 | 0.630 |
Why?
| | DNA, Neoplasm | 1 | 2018 | 146 | 0.570 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2015 | 104 | 0.540 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 2015 | 15 | 0.500 |
Why?
| | Gene Rearrangement, B-Lymphocyte | 1 | 2015 | 6 | 0.490 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2015 | 7 | 0.490 |
Why?
| | Tumor Microenvironment | 4 | 2024 | 222 | 0.460 |
Why?
| | Plasma Cells | 1 | 2015 | 221 | 0.430 |
Why?
| | Cell Differentiation | 1 | 2015 | 648 | 0.390 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 11 | 0.390 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2012 | 18 | 0.390 |
Why?
| | Bone Marrow | 5 | 2022 | 356 | 0.380 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 54 | 0.380 |
Why?
| | Carcinoembryonic Antigen | 1 | 2011 | 14 | 0.370 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 3 | 2024 | 112 | 0.370 |
Why?
| | Calcitonin | 1 | 2011 | 30 | 0.370 |
Why?
| | Antigens, CD | 1 | 2012 | 216 | 0.360 |
Why?
| | Carcinoma | 1 | 2011 | 139 | 0.330 |
Why?
| | Myogenin | 1 | 2008 | 4 | 0.320 |
Why?
| | Muscle Fibers, Slow-Twitch | 1 | 2008 | 12 | 0.320 |
Why?
| | Muscle Fibers, Fast-Twitch | 1 | 2008 | 14 | 0.320 |
Why?
| | Paraproteinemias | 2 | 2022 | 72 | 0.300 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2024 | 556 | 0.300 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 1000 | 0.280 |
Why?
| | Humans | 30 | 2024 | 50201 | 0.260 |
Why?
| | Gene Expression Profiling | 3 | 2016 | 1029 | 0.250 |
Why?
| | Pancytopenia | 3 | 2016 | 37 | 0.240 |
Why?
| | Neoplasm, Residual | 3 | 2022 | 160 | 0.220 |
Why?
| | Embolization, Therapeutic | 2 | 2021 | 88 | 0.190 |
Why?
| | Treatment Outcome | 7 | 2022 | 5203 | 0.190 |
Why?
| | Neoplasms, Plasma Cell | 2 | 2020 | 37 | 0.190 |
Why?
| | Middle Aged | 11 | 2021 | 12356 | 0.190 |
Why?
| | Cryosurgery | 1 | 2021 | 36 | 0.190 |
Why?
| | Prognosis | 5 | 2024 | 1963 | 0.180 |
Why?
| | Plasmacytoma | 1 | 2020 | 40 | 0.170 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 639 | 0.160 |
Why?
| | Female | 15 | 2024 | 26829 | 0.160 |
Why?
| | Ploidies | 1 | 2018 | 11 | 0.150 |
Why?
| | Kidney Diseases | 1 | 2020 | 212 | 0.150 |
Why?
| | Male | 11 | 2024 | 25572 | 0.140 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2017 | 36 | 0.140 |
Why?
| | Cell Cycle | 1 | 2018 | 226 | 0.140 |
Why?
| | CA-125 Antigen | 1 | 2016 | 17 | 0.140 |
Why?
| | Chromosome Deletion | 1 | 2017 | 140 | 0.130 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2016 | 11 | 0.130 |
Why?
| | Anemia, Aplastic | 1 | 2016 | 10 | 0.130 |
Why?
| | Electrophoresis, Capillary | 1 | 2015 | 10 | 0.130 |
Why?
| | In Situ Hybridization | 1 | 2015 | 64 | 0.130 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 214 | 0.120 |
Why?
| | V(D)J Recombination | 1 | 2015 | 4 | 0.120 |
Why?
| | RNA, Messenger | 2 | 2015 | 1097 | 0.120 |
Why?
| | Immunophenotyping | 1 | 2015 | 111 | 0.120 |
Why?
| | Diagnosis, Differential | 3 | 2016 | 1041 | 0.120 |
Why?
| | Fatal Outcome | 1 | 2015 | 195 | 0.120 |
Why?
| | Immunoglobulin Light Chains | 1 | 2015 | 82 | 0.120 |
Why?
| | Prealbumin | 1 | 2014 | 21 | 0.110 |
Why?
| | Bone Marrow Neoplasms | 1 | 2014 | 13 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 321 | 0.110 |
Why?
| | Hodgkin Disease | 1 | 2014 | 45 | 0.110 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 456 | 0.110 |
Why?
| | Parvoviridae Infections | 1 | 2013 | 20 | 0.110 |
Why?
| | Parvovirus B19, Human | 1 | 2013 | 17 | 0.110 |
Why?
| | Amyloidosis | 1 | 2014 | 78 | 0.110 |
Why?
| | Partial Thromboplastin Time | 1 | 2012 | 12 | 0.110 |
Why?
| | Prothrombin Time | 1 | 2012 | 18 | 0.110 |
Why?
| | Lymph Nodes | 1 | 2015 | 258 | 0.100 |
Why?
| | Cardiomyopathies | 1 | 2014 | 116 | 0.100 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2013 | 55 | 0.100 |
Why?
| | Afibrinogenemia | 1 | 2012 | 5 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 921 | 0.100 |
Why?
| | Plasma Exchange | 1 | 2012 | 23 | 0.100 |
Why?
| | Phenotype | 1 | 2015 | 732 | 0.100 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2012 | 20 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 824 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2015 | 973 | 0.100 |
Why?
| | Glycoproteins | 1 | 2012 | 115 | 0.100 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2012 | 8 | 0.100 |
Why?
| | Hepatitis C | 1 | 2012 | 81 | 0.090 |
Why?
| | Transplantation, Autologous | 2 | 2024 | 463 | 0.090 |
Why?
| | Aged | 8 | 2017 | 9505 | 0.090 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2011 | 23 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 1356 | 0.090 |
Why?
| | Splenic Neoplasms | 1 | 2009 | 2 | 0.090 |
Why?
| | Gene Expression | 1 | 2012 | 612 | 0.080 |
Why?
| | Thyroid Neoplasms | 1 | 2011 | 113 | 0.080 |
Why?
| | Myelodysplastic Syndromes | 1 | 2009 | 79 | 0.080 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2008 | 96 | 0.080 |
Why?
| | Hemangioma | 1 | 2009 | 84 | 0.080 |
Why?
| | HIV Infections | 1 | 2012 | 356 | 0.080 |
Why?
| | Protein Processing, Post-Translational | 1 | 2008 | 154 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2008 | 1587 | 0.070 |
Why?
| | Positron-Emission Tomography | 2 | 2021 | 288 | 0.070 |
Why?
| | Muscle Proteins | 1 | 2008 | 320 | 0.060 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2005 | 34 | 0.060 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 96 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 1176 | 0.060 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2005 | 131 | 0.060 |
Why?
| | Imidazoles | 1 | 2005 | 128 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 107 | 0.060 |
Why?
| | Ferritins | 1 | 2024 | 30 | 0.060 |
Why?
| | Pyridines | 1 | 2005 | 132 | 0.060 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 964 | 0.060 |
Why?
| | Pyrimidines | 1 | 2005 | 192 | 0.060 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 123 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2005 | 378 | 0.050 |
Why?
| | Adult | 4 | 2021 | 13486 | 0.050 |
Why?
| | Mediastinum | 1 | 2021 | 21 | 0.050 |
Why?
| | Dexamethasone | 1 | 2024 | 434 | 0.050 |
Why?
| | Vincristine | 1 | 2021 | 85 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2023 | 329 | 0.050 |
Why?
| | Axilla | 1 | 2021 | 91 | 0.050 |
Why?
| | Prednisone | 1 | 2021 | 101 | 0.050 |
Why?
| | Pelvis | 1 | 2021 | 67 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2021 | 164 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2021 | 205 | 0.040 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2021 | 190 | 0.040 |
Why?
| | Tumor Burden | 1 | 2020 | 131 | 0.040 |
Why?
| | Disease Progression | 2 | 2016 | 821 | 0.040 |
Why?
| | Doxorubicin | 1 | 2021 | 234 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1390 | 0.040 |
Why?
| | Adolescent | 1 | 2011 | 6459 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2024 | 2188 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 630 | 0.040 |
Why?
| | Cohort Studies | 1 | 2020 | 1414 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 36 | 0.030 |
Why?
| | Melphalan | 1 | 2016 | 173 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 450 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 670 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 181 | 0.030 |
Why?
| | Reed-Sternberg Cells | 1 | 2014 | 2 | 0.030 |
Why?
| | HIV Seronegativity | 1 | 2014 | 3 | 0.030 |
Why?
| | Thalidomide | 1 | 2016 | 374 | 0.030 |
Why?
| | Heterozygote | 1 | 2014 | 82 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 579 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 409 | 0.030 |
Why?
| | Mice | 1 | 2023 | 5673 | 0.030 |
Why?
| | Fibrinogen | 1 | 2012 | 32 | 0.030 |
Why?
| | Risk Assessment | 1 | 2017 | 1255 | 0.030 |
Why?
| | Blood Coagulation | 1 | 2012 | 58 | 0.030 |
Why?
| | Survival Rate | 1 | 2015 | 906 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2015 | 749 | 0.030 |
Why?
| | Reference Values | 1 | 2012 | 309 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2013 | 179 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2024 | 6190 | 0.020 |
Why?
| | Biopsy | 1 | 2014 | 592 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 2909 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 3158 | 0.020 |
Why?
| | Splenectomy | 1 | 2009 | 34 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2012 | 959 | 0.020 |
Why?
| | Blood Transfusion | 1 | 2009 | 127 | 0.020 |
Why?
| | Animals | 1 | 2023 | 13141 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 1160 | 0.020 |
Why?
| | Laparoscopy | 1 | 2009 | 170 | 0.020 |
Why?
| | Cell Division | 1 | 2005 | 293 | 0.010 |
Why?
| | Phosphorylation | 1 | 2005 | 525 | 0.010 |
Why?
| | Cell Survival | 1 | 2005 | 590 | 0.010 |
Why?
|
|
Alapat's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|